PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain

Phase 3

Completed

Conditions: Pain, Postoperative

Interventions: Drug: DIC075V (intravenous diclofenac sodium)

First Posted Date: 2008-07-31

Last Posted Date: 2021-10-13

Lead Sponsor: Pfizer

Target Recruit Count: 1050

Registration Number: NCT00726388

Locations: 🇺🇸
Staten Island University Hospital, Staten Island, New York, United States
🇺🇸
UPMC-St. Margaret's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Tulane Univ. Medical Center, New Orleans, Louisiana, United States

and more 41 locations

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Phase 1

Completed

Conditions: Lymphoma, B-Cell

Interventions: Drug: Inotuzumab Ozogamicin (CMC-544)
Drug: Rituximab (Rituxan)

First Posted Date: 2008-07-30

Last Posted Date: 2019-03-15

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT00724971

Locations: 🇯🇵
Nagoya Daini Red Cross Hospital, Aichi, Japan
🇯🇵
Tokai University Hospital, Kanagawa, Japan
🇯🇵
National Cancer Center Hospital, Tokyo, Japan

and more 1 locations

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: PF-04191834
Drug: zileuton
Drug: Placebo

First Posted Date: 2008-07-28

Last Posted Date: 2013-02-01

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT00723021

Locations: 🇺🇸
Pfizer Investigational Site, Omaha, Nebraska, United States

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Biological: PF-04360365 0.5 mg/kg
Biological: PF-04360365 1 mg/kg
Drug: Placebo
Biological: PF-04360365 3 mg/kg
Biological: PF-04360365 8.5 mg/kg
Biological: PF-04360365 0.1 mg/kg

First Posted Date: 2008-07-25

Last Posted Date: 2022-11-07

Lead Sponsor: Pfizer

Target Recruit Count: 198

Registration Number: NCT00722046

Locations: 🇬🇧
The Shalbourne Suite, Swindon, Wiltshire, United Kingdom
🇬🇧
Kingshill Research Centre, Swindon, Wiltshire, United Kingdom
🇺🇸
Dedicated Phase 1, Phoenix, Arizona, United States

and more 38 locations

A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers

Phase 1

Completed

Conditions: Insomnia

Interventions: Drug: PD 0200390

First Posted Date: 2008-07-25

Last Posted Date: 2011-02-04

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT00722306

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: letrozole
Drug: PD 0332991

First Posted Date: 2008-07-24

Last Posted Date: 2019-11-04

Lead Sponsor: Pfizer

Target Recruit Count: 177

Registration Number: NCT00721409

Locations: 🇺🇸
Central Hematology Oncology Medical group Inc., Alhambra, California, United States
🇺🇸
TORI -US Central Administration (Regulatory Management), Los Angeles, California, United States
🇺🇸
TORI -US Central Administration, Los Angeles, California, United States

and more 87 locations

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

Phase 1

Terminated

Conditions: Renal Insufficiency
Pharmacokinetics

Interventions: Drug: PD 0332334

First Posted Date: 2008-07-24

Last Posted Date: 2010-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT00721422

Locations: 🇺🇸
Pfizer Investigational Site, Miami, Florida, United States

A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections

Completed

Conditions: Systemic Fungal Infections

Interventions: Drug: voriconazole

First Posted Date: 2008-07-24

Last Posted Date: 2011-01-10

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT00721578

Locations: 🇮🇳
Pfizer Investigational Site, New Delhi, India

A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: PF-00868554
Drug: Placebo

First Posted Date: 2008-07-22

Last Posted Date: 2013-08-26

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT00720434

Locations: 🇵🇷
Pfizer Investigational Site, Santurce, Puerto Rico

Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: sunitinib malate

First Posted Date: 2008-07-16

Last Posted Date: 2023-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 1674

Registration Number: NCT00716625

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy